BIORASIS has developed a biosensor aimed to revolutionize the way by which pre-clinical animal research is conducted for drug-development
Biorasis is working towards the development of a miniaturized implantable continuous glucose sensor (CGM) for use in the pre-clinical animal research market. Due to its miniaturized size it is the only CGM that can be used in rodents, which are 98% of the animals used in research for drug-development. The savings from using our sensor as opposed to other technologies, is ca. 84% cost reduction for a 1 month research study.